XXII: 22nd Century Group Company Buyout Price

Brandmark of 22nd Century Group, Inc. (XXII)

22nd Century Group (XXII) is developing low-nicotine tobacco production, monetizing biotech patents through seed licensing. The genetics team is creating innovative varieties to improve human health. This price chart reflects that the Enterprise Value is -4.24. The company's monopoly position is secured by FDA approval and unique bioengineering developments, which create a powerful moat against competitors.

XXII (xxiicentury.com) Total Company Value history from 11/23/2025 to 10/28/2026
Manufactured products of 22nd Century

Investors utilize this metric as an objective business acquisition cost that accounts for the combination of equity and net debt. The current value of -4.24, represented via the market valuation of assets excluding liquidity, reflects the real price of 22nd Century Group (XXII), which remains stable due to the absence of external geopolitical risks and the company's exclusive focus on the US domestic market.